Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells.

Demircan, Muhammed Burak; Mgbecheta, Peter C; Kresinsky, Anne; Schnoeder, Tina M; Schröder, Katrin; Heidel, Florian H; Böhmer, Frank D

Demircan, Muhammed Burak; Mgbecheta, Peter C; Kresinsky, Anne; Schnoeder, Tina M; Schröder, Katrin; Heidel, Florian H; Böhmer, Frank D.

Afiliación

Demircan MB; Institute of Molecular Cell Biology, CMB, Jena University Hospital, 07745 Jena, Germany.
Mgbecheta PC; Innere Medizin II, Hämatologie und Onkologie, Jena University Hospital, 07747 Jena, Germany.
Kresinsky A; Leibniz Institute on Aging-Fritz Lipman Institute, 07745 Jena, Germany.
Schnoeder TM; Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, 63225 Langen, Germany.
Schröder K; Institute of Molecular Cell Biology, CMB, Jena University Hospital, 07745 Jena, Germany.
Heidel FH; Institute of Molecular Cell Biology, CMB, Jena University Hospital, 07745 Jena, Germany.
Böhmer FD; Leibniz Institute on Aging-Fritz Lipman Institute, 07745 Jena, Germany.

Antioxidants (Basel) ; 11(3)2022 Mar 08.

Article en En | MEDLINE | ID: mdl-35326163

Palabras clave

CRISPR/Cas9-mediated deletion; GKT137831; NADPH oxidase 4 (NOX4); Setanaxib; acute myeloid leukemia (AML); inhibitor; reactive oxygen species (ROS)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Antioxidants (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Antioxidants (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania